Product Information
ZIOPTAN 0.0015% EYE DROP is a brand product labeled by Thea Pharma Inc., priced at $8.4856 per EA under NDC 82584060930. Its NADAC has been published 181 times since Apr 19, 2023.
FDA first approved this application on Feb 10, 2012. Its Orange Book therapeutic-equivalence code is AT.
The High Outlier badge above means this manufacturer's average price in the Tafluprost market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
.015 mg/mL
Manufacturer
Thea Pharma Inc.NDC
82584060930
Classification
Brand
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
TAFLUPROSTApproval Type
New Drug (NDA)
FDA Application
NDA202514FDA Approved
2/10/2012
TE Code
AT
On Market Since
10/28/2022
Pharmacological Classes
Price Statistics
The NADAC for ZIOPTAN 0.0015% EYE DROP has been published 181 times since Apr 19, 2023, and over the history we have for it it has risen 15.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.4856 per EA |
|---|---|
| All-time high | $8.5184 (Dec 11, 2024) |
| All-time low | $7.3424 (Apr 19, 2023) |
| 52-week high | $8.4960 |
| 52-week low | $8.4856 |
| Median price | $8.4932 |
| Average price | $8.3026 |
| Largest weekly change | +8.0% (May 8, 2024) |
| Weeks tracked | 181 |
| Tracking since | Apr 19, 2023 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 71% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Thea Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tafluprost market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Prostaglandin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZIOPTAN 0.0015% EYE DROP?
The current National Average Drug Acquisition Cost (NADAC) for ZIOPTAN 0.0015% EYE DROP, manufactured by Thea Pharma Inc., is $8.4856 per EA (NDC 82584060930), effective Sep 30, 2026.
How has the price of ZIOPTAN 0.0015% EYE DROP changed over time?
Over the history we have for it, the NADAC for ZIOPTAN 0.0015% EYE DROP has risen 15.6%. It has been tracked across 181 weekly CMS publications since Apr 19, 2023.
What are the highest and lowest recorded NADAC prices for ZIOPTAN 0.0015% EYE DROP?
Since Apr 19, 2023, the NADAC for ZIOPTAN 0.0015% EYE DROP has ranged from a low of $7.3424 (Apr 19, 2023) to a high of $8.5184 (Dec 11, 2024), with a median of $8.4932 per EA.
Are there cheaper alternatives to ZIOPTAN 0.0015% EYE DROP?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TAFLUPROST 0.0015% EYE DROP, is $2.4535 per EA — about 71% below ZIOPTAN 0.0015% EYE DROP.
Who manufactures ZIOPTAN 0.0015% EYE DROP?
ZIOPTAN 0.0015% EYE DROP (NDC 82584060930) is labeled by Thea Pharma Inc., and CMS classifies it as a brand product.